The policy is a drug-compounding framework, not a supplement pathway, but it changes the regulatory backdrop for peptide products, drug preclusion arguments, and gray-market competition.
AHPA, CHPA, CRN, and UNPA say placing ODS under the Office of Nutrition Research would add a layer of bureaucracy. NIH is accepting comments through October 28.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
The agency’s editorial identifies needs across six areas, including new methods for novel products, gut microbiome data, and AI-supported risk assessment.
The Council for Responsible Nutrition says its Morning Consult survey also found that three in four adults use supplements and that cost is the most commonly cited barrier.
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Denis Neville, founder and CEO of CoreFX Ingredients, about the launch of CreaSHLD-IN.